FINWIRES · TerminalLIVE
FINWIRES

Mayank Cattle Food Launches New Multivitamin Product for Dairy Animals; Shares Up 4%

By

Mayank Cattle Food (BOM:544106) has launched a new cattle feed product named "Mayank Vita H Liquid" in the Indian market, according to a Wednesday filing to the BSE.

Mayank Vita H Liquid is a combination of multivitamins and minerals specially formulated for livestock health and productivity. It helps to address nutritional deficiencies, supports metabolic functions, and enhances overall performance in dairy animals.

The company expects the new product to boost revenue, diversify income sources, and enhance market penetration.

The company's shares were up over 4% in recent trade.

Related Articles

Asia

Weiye Flags High Concentration of Shareholding

Weiye Holdings (HKG:1570) flagged a high concentration of shareholding in the firm's shares following a request from the Hong Kong Stock Exchange, according to a filing with the city's bourse Tuesday.The residential and commercial property developer's shares fell nearly 2% in late morning trade Wednesday.According to the notice, 20 shareholders collectively controlled 83.50% of the company's issued share capital, while another 13.12% of shares were registered under HKSCC Nominees' name, leaving only 3.38% of the issued shares in the hands of other shareholders.This meant that the shares may not have a genuine market and prices could fluctuate "substantially" even with a small number of shares traded, the firm said.

$HKG:1570
Asia

Postal Savings Bank of China Appoints Chief Compliance Officer

Postal Savings Bank of China (HKG:1658, SHA:601658) appointed President Lu Wei as chief compliance officer, effective Tuesday, according to a same-day Hong Kong bourse filing.Hong Kong-listed shares of the lender were down nearly 1% in Wednesday's late morning trade.Lu previously held senior roles at China CITIC Bank (HKG:0998, SHA:601998) and also served as chairman of CITIC Trust.

$HKG:0998$HKG:1658$SHA:601658$SHA:601998
Asia

Junshi Biosciences Drug Meets Main Goal of Lung Cancer Study

Shanghai Junshi Biosciences (HKG:1877, SHA:688180) said its cancer therapy toripalimab met the main goal of a phase 3 study in lung cancer, according to a Tuesday filing with the Hong Kong bourse.The company's shares fell over 3% in late morning trade Wednesday.Based on the final analysis of the trial, the drug met the primary endpoints of event-free survival and major pathological response in subjects with stage II-III non-small cell lung cancer, the firm said.The company now plans to seek regulatory approval to expand the drug's coverage from perioperative treatment of patients with resectable stage III non-small cell lung cancer to those with stage II-III of the disease.

$HKG:1877$SHA:688180